Meeting
2017 Gastrointestinal Cancers Symposium
Erbitux metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.
Authors
Carmine Pinto
Medical Oncology Unit, IRCCS-Arcispedale S. Maria Nuova, OECI Clinical Cancer Center, Reggio Emilia, Italy
Carmine Pinto , Nicola Normanno , Armando Orlandi , Evaristo Maiello , Domenico Bilancia , Domenico C. Corsi , Emiliano Tamburini , Salvatore Pisconti , Francesco Ferraú , Francesco Di Costanzo , Stefania Gori , Bruno Daniele , Giuseppe Tonini , Alberto Zaniboni , Hector Soto-parra , Giovanni Luca Frassinetti , Rosario Vincenz Iaffaioli , M. Giulia Zampino , Lazzaro Repetto , Carlo Antonio Barone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02484833
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS810)
DOI
10.1200/JCO.2017.35.4_suppl.TPS810
Abstract #
TPS810
Poster Bd #
O10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).
First Author: Nicola Normanno
Poster
2020 Gastrointestinal Cancers Symposium
Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.
First Author: Madiha Naseem
Poster
2020 Gastrointestinal Cancers Symposium
Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.
First Author: Francesca Battaglin
Poster
2018 ASCO Annual Meeting
Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.
First Author: Madiha Naseem